Scilex Holding Company Restricted Cash and Cash Equivalents
Scilex Holding Company (SCLX) had Restricted Cash and Cash Equivalents of $0 as of 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-04-10
- 2025-12-31: Restricted Cash and Cash Equivalents $0.00.
- 2024-12-31: Restricted Cash and Cash Equivalents $0.00.
- 2024-09-30: Restricted Cash and Cash Equivalents $8.04M.
- 2024-06-30: Restricted Cash and Cash Equivalents $2.78M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-04-10 |
| 2024-12-31 | $0.00 10-K · filed 2026-04-10 |
| 2024-09-30 | $8.04M 10-Q · filed 2025-01-17 |
| 2024-06-30 | $2.78M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $956.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $808.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $26.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.00M 10-Q · filed 2023-08-11 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |